Baxter announces $100M investment in biopharma solutions at German sterile fill/finish manufacturing facility

Biopharma Solutions, Halle/Westfalen, Germany

Investment will add a syringe filling line, additional liquid and lyophilized (freeze dried) vial capacity and expand manufacturing footprint

This facility is operated by BioPharma Solutions (BPS), a business unit of Baxter that specializes in partnering with leading pharmaceutical and biotech companies on the development and contract manufacturing of drug product for parenteral (injectable) pharmaceuticals.

Construction on the new manufacturing building is expected to begin in 2022 and be completed in 2024. This strategic investment will expand the BPS manufacturing footprint and add state-of-the-art equipment designed to help products achieve stability and improved shelf life through lyophilization (freeze drying).

Construction will also add an aseptic syringe filling line, enabling BPS to meet the growing demand for this delivery platform in both Europe and the United States. Pre-filled syringes can enhance efficiency and ease-of-use for clinicians and have potential to minimize microbial contamination and reduce medication dosing errors during medication preparation, which are key considerations for patient safety.

'Baxter’s manufacturing site in Halle/Westfalen is one of the most advanced facilities in our global network and has seen significant growth over the last several years,' said Marie Keeley, general manager, Baxter BioPharma Solutions.

'By making this investment, we are building on recent expansions to help ensure this facility can serve our partners at the highest level now and well into the future.'

Baxter’s Halle/Westfalen, Germany site has more than 60 years of experience and is recognized as a world-class manufacturer of cytotoxic and highly potent drugs, offering dedicated clinical development through commercial production with integrated technologies and services, including barrier technology that helps maintain a high level of containment when manufacturing sensitive and sophisticated drugs.

The site also has broad sterile manufacturing capabilities and areas of focus, complies with current good manufacturing practices (cGMP) regulations, features dedicated production areas and is designed to deliver products with optimum efficiency and speed to market.

Baxter’s Halle/Westfalen facility was previously expanded in 2015, which added capacity and new technologies to stay on the leading edge of manufacturing parenteral oncology therapies. In addition, Baxter’s Halle/Westfalen facility is engaged in multiple collaborations to provide sterile manufacturing services for COVID-19 vaccines. 


About Baxter's BioPharma Solutions Business 
Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise, sterile manufacturing solutions, parenteral delivery systems and customized support services needed to meet the unique challenges that parenteral products face. For more information, please visit: biopharmasolutions.baxter.com. 

About Baxter 
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook. 

This release includes forward-looking statements concerning Baxter BioPharma Solutions, including the proposed investment in the expansion of its facilities. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the company’s ability to finance the planned investment and to develop new products or enhancements; satisfaction of regulatory and 3 other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements. 


Baxter and BioPharma Solutions are registered trademarks of Baxter International Inc.